Hong Kong Stock Moves: SKB BIO Surges Over 4% Before Noon as New Dual-Load ADC Drug Gets Clinical Trial Approval
Stock News
Aug 06
SKB BIO (06990) climbed more than 4% before the midday trading session, with shares last up 3.8% to HK$510.5, on turnover of HK$95.924 million.
The company recently announced that it has received a clinical trial approval notice from the Center for Drug Evaluation of the National Medical Products Administration for its novel dual-load ADC drug candidate, SKB565, intended for the treatment of advanced solid tumors. This marks the first dual-load antibody-drug conjugate from SKB BIO to enter the clinical stage, with the approval of SKB565 representing a key step forward in the company's "ADC+IO" integrated development strategy.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.